New Data on Ceplene® Cancer Immunotherapy to be Presented at the 2016 AACR Annual Meeting


Re-distribution of cytotoxic T-Cell Subsets During Therapy with Ceplene Predicts Overall Survival in Patients with Acute Myeloid Leukemia NEW YORK, March 17, 2016 /PRNewswire/ — Immune Oncology Pharmaceuticals, a clinical-stage biopharmaceutical company and a subsidiary of Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced today that new clinical pharmacology and outcomes data with Ceplene (histamine dihydrochloride) will be…

This content is for Free Elite Membership members only.
Log In Register